Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Last trade$165.30
Day change-$0.01 (-0.01%)
Day range$162.16 – $166.20
Volume445,325
Market cap$16.73B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$16.73B
Price / earnings
23.82×
Price / book
4.31×
Price / sales
4.52×
EV / sales
4.35×
EV / EBITDA
16.2×
Profitability
Earnings per share
$6.94
Return on assets
12.48%
Return on equity
18.11%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.04×
Quick ratio
1.97×
Cash ratio
0.65×
Cash flow
Price / cash flow
15.7×
Price / free cash flow
16.09×
Free cash flow
$1.04B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NBIX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.12B
$959M
$814.5M
$805.5M
$794.9M
$687.5M
$572.6M
$627.7M
Cost of revenue
$26.6M
$23.2M
$13.8M
$17.6M
$13M
$10.3M
$9.2M
$9.3M
Gross profit
$1.1B
$935.8M
$800.7M
$787.9M
$781.9M
$677.2M
$563.4M
$618.4M
Selling, general and administrative
$366.3M
$439.7M
$318.5M
$301.8M
$291.6M
$286.3M
$276.5M
$287.8M
Research and development
$351.8M
$326.7M
$296.2M
$258.2M
$250M
$244.3M
$263.2M
$185.6M
Total operating expenses
$764.8M
$784.3M
$635.9M
$577M
$542.9M
$531.6M
$539.8M
$476.4M
Operating income
$331.3M
$151.5M
$164.8M
$210.9M
$239M
$145.6M
$23.6M
$142M
Interest expense
-$300K
-$2.9M
$0
$0
$0
$0
$0
$0
Income before taxes
$283.7M
$162.2M
$246.8M
$239.4M
$291.8M
$159.5M
$14.7M
$162.6M
Income taxes
$77.2M
$17.8M
$48.9M
$85.7M
$82.3M
$52M
$6.8M
$59.5M
Net income
$206.5M
$144.4M
$197.9M
$153.7M
$209.5M
$107.5M
$7.9M
$103.1M
Net income attributable to common shareholders
$206.5M
$144.4M
$197.9M
$153.7M
$209.5M
$107.5M
$7.9M
$103.1M
EBITDA
$403.5M
$161.3M
$193.3M
$235.4M
$249M
$150.9M
$31.3M
$152.1M
Basic earnings per share
$2.03
$1.43
$1.97
$1.54
$2.11
$1.09
$0.08
$1.03
Diluted earnings per share
$1.96
$1.39
$1.91
$1.48
$2.04
$1.06
$0.08
$1.00
Recent news
Company coverage with links to the original publishers.
Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top growth stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company is forecasting year-over-year earnings growth of 60.6% for fiscal 2026, with three analysts revising earnings estimates upward in the last 60 days, bringing the Zacks Consensus Estimate to $10.26 per share.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
In a comparison of two Medical-Drugs sector stocks, Neurocrine Biosciences (NBIX) emerges as the superior value opportunity over Guardian Pharmacy Services (GRDN). NBIX holds a Zacks Rank #2 (Buy) with stronger valuation metrics including a forward P/E of 16.46 versus GRDN's 35.76, a PEG ratio of 0.56 versus 2.20, and a P/B ratio of 4.41 versus 8.37. NBIX also received a Value grade of B compared to GRDN's C grade.
Neurocrine Biosciences (NBIX) is highlighted as a solid growth stock choice, earning a Growth Score of A and Zacks Rank #2. The company demonstrates strong fundamentals including projected EPS growth of 60.5% (vs. industry average of 17.7%), efficient asset utilization with an S/TA ratio of 0.72 (vs. industry average of 0.49), expected sales growth of 37.8%, and positive earnings estimate revisions with an 8.8% surge over the past month.
Neurocrine Biosciences (NBIX) received an upgrade to Zacks Rank #2 (Buy) due to upward trends in earnings estimates. The biopharmaceutical company's consensus estimate for fiscal year 2026 shows no year-over-year change at $10.26 per share, but analysts have raised estimates by 8.2% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.